Retatrutide Cost: Is It FDA Approved, and What Will It Cost Per Month?

Short answer: Retatrutide has no price, because it is not FDA approved and cannot be legally sold. As of November 13, 2026, it is available only inside Lilly's clinical trials and a pre-approval expanded access program; Lilly plans to submit it to the FDA in the first quarter of 2027 and has not announced a price.^[1][2][3] The closest guide is what Lilly charges for its approved sibling, Zepbound: a list price of about $1,086 a month, or $299 to $449 a month paying cash direct from Lilly.^[4][5] Anyone quoting a monthly price for retatrutide today is selling an unapproved product.^[6]

New to eating less? Start with what to eat when you're eating less, the guide the rest of Lighter Days builds on.

This page sets out what is known as of November 13, 2026: approval status, what the approved GLP-1 medications cost today and how those prices came about, how coverage works through employers, Medicare and Medicaid, and why "research" retatrutide sold online is not a cheaper version of anything. What retatrutide is and what its trials found are in our parent explainer, GLP-3 (retatrutide): what it is and when it's expected.

General information, not medical or financial advice. Prices change often. Check current prices and your coverage with your prescriber, pharmacist or insurer.

Is retatrutide FDA approved?

No. Retatrutide is not approved by the FDA or by any other regulator as of November 13, 2026. Lilly describes it as an investigational molecule that is legally available only to participants in its clinical trials,^[2] plus a pre-approval expanded access program for a narrow group of adults with severe obesity who cannot join a trial, requested by a physician.^[3] On July 23, 2026, Lilly said it is completing the manufacturing data package for a Biologics License Application and plans to submit retatrutide for US approval in the first quarter of 2027.^[1] A submission is not an approval; neither Lilly nor the FDA has given a decision date.

How much will retatrutide cost per month?

Nobody knows yet, and any figure you see is a guess or a gray-market quote. We found no price, price range or pricing plan for retatrutide in Lilly's releases as of this date. Three facts frame the eventual answer:

• Lilly's approved obesity drug is the anchor. Zepbound (tirzepatide) has a list price of about $1,086 to $1,088 a month by the White House's figures, and Lilly sells it direct to people paying cash for $299 to $449 a month depending on dose.^[4][7][5]
• Launch list prices have clustered around $1,000 to $1,300 a month. Zepbound launched in November 2023 at a list price of $1,059.87 a month,^[8] and Wegovy in June 2021 at $1,297 a month.^[9]
• Cash prices have been falling. In its November 2025 agreement with the US government, Lilly said it would launch new medicines with "a more balanced pricing approach across developed nations", and priced its then-unapproved pill, orforglipron, in advance at $149 to $399 a month.^[5] The agreement does not mention retatrutide.

So the honest answer to "retatrutide price per month" is: no legal price exists, and the price at launch is Lilly's decision, made around the time of approval.

What do approved GLP-1 medications cost today?

Medication	Maker	List price (before insurance)	Cash price direct from the maker or via TrumpRx
Zepbound (tirzepatide) injection	Lilly	About $1,086–$1,088 a month[4][7]	Vials: $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) a month.[10] Multi-dose pen: $299 to $449.[5]
Wegovy (semaglutide) injection	Novo Nordisk	$1,349 a month; falling to $675 on January 1, 2027[7][11]	Average $350, as low as $199[7]
Wegovy (semaglutide) pill	Novo Nordisk	$1,349 a month[7]	From $149 for the lowest dose; $299 for the 9 mg and 25 mg doses[7][12]
Ozempic (semaglutide), type 2 diabetes	Novo Nordisk	$1,028 a month; falling to $675 on January 1, 2027[7][11]	Average $350, as low as $199[7]
Retatrutide	Lilly	None: not approved, cannot be legally sold[2]

Prices as published by the sources cited, checked November 13, 2026. "As low as" prices usually apply to the starting dose or to an introductory offer. Payments made through TrumpRx do not count toward an insurance deductible or out-of-pocket maximum, KFF notes.^[13]

Two things in that table are easy to misread. The list price is what the maker charges wholesalers before rebates; few people pay it, but it drives coinsurance and deductibles for people with insurance. The cash price is a separate, lower price for people paying out of pocket; Novo said its January 2027 list price cut does not change its direct-to-patient self-pay prices.^[11]

How did GLP-1 prices come down?

• November 6, 2025: the White House announced agreements with Lilly and Novo Nordisk. Zepbound bought through TrumpRx would average $346 a month, Ozempic and Wegovy $350; the Medicare price of Ozempic, Wegovy, Mounjaro and Zepbound would be $245, with a $50 monthly copay for eligible beneficiaries.^[4]
• December 1, 2025: Lilly lowered its Zepbound vial cash prices to $299, $399 and $449 a month by dose.^[10]
• January 5, 2026: Novo launched the Wegovy pill from $149 a month for cash buyers.^[12]
• February 5, 2026: TrumpRx.gov launched, a government site that lists these cash prices.^[7]
• February 24, 2026: Novo announced it would cut the list price of Wegovy and Ozempic to $675 a month from January 1, 2027, reductions of about 50% and 35%.^[11]
• July 1, 2026: the Medicare GLP-1 Bridge began (below).^[14]

If retatrutide is approved, it will launch into this market: list prices under pressure, cash programs already below $500 a month for its sibling, and a government price for Medicare. None of that sets its price, but it is the context Lilly will price into.

Will insurance cover retatrutide?

Not until it is approved, and then plan by plan. For the GLP-1 medications approved for obesity today, coverage is patchy:

• Employer plans. In KFF's 2026 Employer Health Benefits Survey, 18% of firms with 200 or more workers covered GLP-1 medications used primarily for obesity, similar to 19% the year before. Coverage rose with size: 16% of firms with 200 to 999 workers, 29% with 1,000 to 4,999, and 33% with 5,000 or more.^[15]
• Medicare. Medicare Part D is barred by law from covering drugs used for obesity alone, KFF explains.^[16] The Medicare GLP-1 Bridge, a CMS demonstration that runs from July 1, 2026 to December 31, 2027, lets eligible Part D beneficiaries get certain GLP-1 medications for a $50 copay.^[14] The drugs named for CMS's related BALANCE model are Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen and Foundayo; retatrutide is not on the list.^[17]
• Medicaid. Coverage for obesity is a state choice. KFF counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in October 2025.^[16] Under BALANCE, state Medicaid agencies can join from May 2026 through January 1, 2027.^[17]

A new drug usually reaches insurance formularies months after approval, once plans have reviewed it and negotiated with the maker. Expect the same for retatrutide, and expect prior authorization rules like those for its siblings.

What can you do about cost today?

• Ask about approved options. If cost is the barrier, ask your prescriber whether an approved medication fits, and compare your plan's price with the makers' cash programs; which is cheaper depends on your coverage.
• Check your plan's rules. Coverage, prior authorization and step rules differ by employer and plan, and change at renewal.^[15]
• If you are on Medicare Part D, ask whether you qualify for the GLP-1 Bridge.^[14]
• Plan for the food side too. Whatever medication you take, eating less means fewer chances to get protein, fluids and micronutrients. The 2025 joint advisory on nutrition with GLP-1 therapy puts protein first and suggests small, frequent, nutrient-dense meals.^[21] Our GLP-1 nutrition guide maps it out, and the nutrition gap calculator shows which nutrients a smaller plate tends to miss.

What retatrutide's trials reported, dose by dose, is in retatrutide adverse events in the trials.

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it has nothing to do with retatrutide. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.